Dimetapp Elixir
NDC Package 80070-310-04
Package Information
Dimetapp (brompheniramine maleate, dextromethorphan hydrobromide, and phenylephrine hydrochloride) elixirs is do not take more than 6 doses in any 24-hour periodmeasure only with dosage cup providedkeep dosage cup with productmL = milliliteragedoseadults and children 12 years and over20 mL every 4 hourschildren 6 to under 12 years10 mL every 4 hourschildren under 6 yearsdo not use do not take more than 6 doses in any 24-hour periodmeasure only with dosage cup providedkeep dosage cup with productmL = milliliteragedoseadults and children 12 years and over20 mL every 4 hourschildren 6 to under 12 years10 mL every 4 hourschildren under 6 yearsdo not use. This formulation utilizes a elixir delivery system. Marketed by Foundation Consumer Brands, this product is identified by NDC 80070-310 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 1090463 - brompheniramine maleate 1 MG / dextromethorphan HBr 5 MG / phenylephrine HCl 2.5 MG in 5 mL Oral Solution
- RxCUI: 1090463 - brompheniramine maleate 0.2 MG/ML / dextromethorphan hydrobromide 1 MG/ML / phenylephrine hydrochloride 0.5 MG/ML Oral Solution
- RxCUI: 1090463 - brompheniramine maleate 1 MG / dextromethorphan hydrobromide 5 MG / phenylephrine hydrochloride 2.5 MG per 5 ML Oral Solution
- RxCUI: 1090463 - brompheniramine maleate 2 MG / dextromethorphan hydrobromide 10 MG / phenylephrine hydrochloride 5 MG per 10 ML Oral Solution
- RxCUI: 1236048 - diphenhydrAMINE HCl 6.25 MG / phenylephrine HCl 2.5 MG in 5 mL Oral Solution
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Sigma-1 Agonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Receptor Agonists - [MoA] (Mechanism of Action)
- Uncompetitive N-methyl-D-aspartate Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Uncompetitive NMDA Receptor Antagonists - [MoA] (Mechanism of Action)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 80070 - Foundation Consumer Brands
- 80070-310 - Dimetapp
- 80070-310-04 - 1 BOTTLE in 1 CARTON / 118 mL in 1 BOTTLE
- 80070-310 - Dimetapp
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (80070-310). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 80070-310-04 identifies a specific commercial package of 1 bottle in 1 carton / 118 ml in 1 bottle of Dimetapp Cold And Cough, a human over the counter drug labeled by Foundation Consumer Brands. This elixir is formulated for oral use and contains brompheniramine maleate; dextromethorphan hydrobromide; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Foundation Consumer Brands on September 15, 2021.
How is this Foundation Consumer Brands product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 80070031004. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.